Sutureless Aortic Valve: Early And Mid-Term Results At A Single Center

Background: Prolonged life expectancy has increased the number of elderly high risk patients referred for surgical aortic valve replacement (AVR). These referred high risk patients may benefit from sutureless bioprosthesis procedures which reduce mortality and morbidity.Objectives: To present our initial experience with sutureless aortic bioprotheses, including clinical and echocardiographic results, in elderly high risk patients referred for AVR.Methods: Forty patients (15 males, mean age 78 7 years) with symptomatic severe aortic stenosis underwent AVR with the 3F Enable (TM) or Perceval (TM) sutureless bioprosthesis during the period December 2012 to May 2014. Mean logistic EuroScore was 10 +/- 3%. Echocardiography was performed preoperatively, intraoperatively, at discharge and at follow-up.Results:There was no in-hospital mortality. Nine patients (22%) underwent minimally invasive AVR via a right anterior mini-thoracotomy and one patient via a J-incision. Four patients underwent concomitant coronary aortic bypass graft, two needed intra-operative repositioning of the valve, one underwent valve exchange due to inappropriate sizing, three (7.5%) had a peri-operative stroke with complete resolution of neurologic symptoms, and one patient (2.5%) required permanent pacemaker implantation due to complete atrioventricular block. Mean pre-operative and postoperative gradients were 44 +/- 14 and 13 +/- 5 mmHg, respectively. At follow-up, 82% of patients were in New York Heart Association functional class I and II.Conclusions: Sutureless AVR can be used safely in elderly high risk patients with relatively low morbidity and mortality. The device can be safely implanted via a minimally invasive incision. Mid-term hemodynamic results are satisfactory, demonstrating significant clinical improvement.